Beijing Foyou Pharma CO.(SH:601089) Shang Hai Zheng Quan Bao·2025-09-29 23:01Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II), which will enhance the company's product line and market competitiveness [1][5]. Drug Registration Certificate Details - The drug is a combination of Candesartan Cilexetil (16mg) and Hydrochlorothiazide (12.5mg) and is indicated for adults with primary hypertension who do not achieve adequate blood pressure control with either drug alone [1][2]. R&D Investment - The total R&D investment for this drug has reached RMB 4.8441 million (unaudited) as of the announcement date [3]. Market Status of Similar Drugs - In 2024, the sales revenue of Candesartan Cilexetil and Hydrochlorothiazide combination in China was approximately RMB 153.76 million, with significant contributions from urban public hospitals and community health centers [4].